This review synthesizes recent molecular insights into how Nrf2–Keap1 signaling governs NLRP3 inflammasome activity, delineates the consequences of axis dysregulation for mitochondrial integrity and dopaminergic survival and critically appraises emerging pharmacological approaches aimed at restoring this balance to modify PD progression. This evidence concerns the gene KEAP1 and Parkinson disease.